Breaking News

Safety data from Wave Life's Exon-51 SAD DMD trial seems reasonably clean, says Mizuho. Mizuho analyst Salim Syed notes that Wave Life Sciences disclosed safety data from its Phase 1 Exon-51 SAD DMD trial, and based on this Phase 1 trial and preclinical work, the company has selected two doses to move forward into its Phase 2/3 trial, 3mg/kg and 4.5mg/kg. The analyst believes the safety data seems "reasonably clean," and that the Street should be not be getting hung up on the reported adverse events. Syed reiterates a Buy rating and $65 price target on the shares.

Wave Life Sciences suvodirsen data with little read-through for efficacy, says SVB Leerink. SVB Leerink analyst Mani Foroohar says that Wave Life Sciences' first-in-human safety data from the Phase I trial of suvodirsen in exon 51 skipping-amenable Duchenne Muscular Dystrophy shows that it was generally sage and well-tolerated up to the 5mg/kg dose, and notes the company has selected the 3.0mg/kg and 4.5mg/kg doses to pivotal trials. While the stock is trading down and investors seem to see negative read-throughs for the potential efficacy of suvodirsen at 5mg/kg, given that drisapersen was dosed at 6mg/kg in clinical trials, the analyst believes that due to differences in chemistry between the compounds, comparison of doses between drugs is not appropriate proxy of potential efficacy. Foroohar maintains his 30% probability of success on the suvodirsen program and reiterates an Outperform rating on the shares.